
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics has demonstrated significant momentum with a projected acceleration in procedure volumes exceeding 50% year-over-year by the second half of 2026, driven by effective commercial initiatives. The company recently reported strong quarterly placements of capital systems, achieving 58 installations, which surpassed previous guidance and reflects a robust demand in the face of a challenging macroeconomic environment. With Q3'25 sales of $83.3 million, representing a 43% year-over-year increase, Procept BioRobotics not only surpassed revenue expectations but also showcased the potential for sustainable double-digit growth, particularly in benign prostatic hyperplasia treatments through increased utilization and new surgery centers.
Bears say
PROCEPT BioRobotics Corp has experienced a significant negative outlook due to its fourth-quarter revenue falling 19% below consensus expectations, coupled with a downward revision of fiscal year 2026 sales guidance that is 5% lower than market consensus. The company noted challenges in handpiece sales resulting from the removal of price discounts for bulk purchases and inventory de-stocking, which further exacerbates its financial difficulties. Additionally, external pressures on hospitals related to profitability following COVID-19 and broader macroeconomic disruptions contribute to concerns regarding the company's future growth projections and overall market performance.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares